Roche Secures Global Rights to Simcere’s Trispecific B-Cell Antibody in $1.53B Deal
Roche has agreed to pay up to $1.53 billion for global rights to SIM0660, a preclinical trispecific antibody from Simcere Zaiming. The deal includes a $75 million upfront payment and tiered royalties, marking Roche’s second major licensing acquisition in a week as it expands its pipeline for B-cell-mediated diseases.